Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jun 23, 2023
TickeronGET DAILY SIGNALS
AMGN Experiences a Positive Boost of +4.43% with Tickeron's Automated Trading

AMGN Experiences a Positive Boost of +4.43% with Tickeron's Automated Trading

The Swing trader: Top High-Volatility Stocks v.2 (TA) AI trading robot has demonstrated its prowess once again, delivering impressive gains of +4.43% while trading AMGN (Amgen) over the previous week. This article will delve into the recent earnings results of AMGN and analyze the potential implications for traders.

Analyzing Earnings Results:

AMGN's latest earnings report, released on April 27, showcased the company's strong performance, surpassing expectations with earnings per share (EPS) of $3.98 compared to the estimated $3.82. This positive surprise indicates the company's ability to generate robust profits and highlights its potential for growth.

Market Capitalization:

With 41.92K shares outstanding, AMGN's current market capitalization stands at an impressive $122.14 billion. This figure reflects the market's valuation of the company based on its outstanding shares and demonstrates AMGN's substantial presence in the pharmaceutical industry.

Technical Analysis:

Aside from the encouraging earnings results, technical indicators also suggest a potential shift in AMGN's stock trend. On June 2, 2023, the Relative Strength Index (RSI) Oscillator for AMGN moved out of oversold territory. This development indicates that the stock may be transitioning from a downward trend to an upward trend, presenting an opportunity for traders.

To further analyze this shift, the A.I.dvisor examined 32 instances when the RSI indicator left oversold territory. In 20 out of those 32 cases, the stock price moved higher. This statistical observation implies that the probability of AMGN moving higher after leaving oversold territory is approximately 62%.

Implications for Traders:

Considering the positive earnings report, with AMGN surpassing EPS estimates, combined with the technical analysis indicating a potential shift in the stock's trend, traders may view this as an opportune moment. The positive earnings results and the RSI indicator's movement out of oversold territory provide a favorable backdrop for considering investment in AMGN, either through buying the stock or call options.

Related Ticker: AMGN

Contributor

Dem Sem's AvatarDem Sem|Expert

AMGN in upward trend: 10-day moving average broke above 50-day moving average on October 16, 2026

The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 43 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 27 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 7%. MIRA experienced the highest price growth at 20%, while SCLX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 31
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 14 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of human therapeutic products based on cellular biology

Industry PharmaceuticalsMajor

Industry
Biotechnology
Address
One Amgen Center Drive
Phone
+1 805 447-1000
Employees
31500
Web
https://www.amgen.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.